CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: Structural basis for inactivation by regioselective O-demethylation

Drug Metabolism and Disposition

Volumn 30, Issue 1, 2002, Pages 74-85

  Uckun, Fatih M ^a   Thoen, Jason ^a   Chen, Hao ^a   Sudbeck, Elise ^a   Mao, Chen ^a   Malaviya, Ravi ^a   Liu, Xing Ping ^a   Chen, Chun Lin ^a  

^a Parker Hughes Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; 4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4' HYDROXPHENYL)AMINO 6 METHOXY 7 HYDROXYQUINAZOLINE; 4 (4' HYDROXYPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE; ALPHA NAPHTHOFLAVONE; AROCLOR 1254; BETA NAPHTHOFLAVONE; CLOFIBRATE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; DEXAMETHASONE; FURAFYLLINE; ISONIAZID; JANEX 1M; JANUS KINASE; JANUS KINASE 3 INHIBITOR; PHENOBARBITAL; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BINDING SITE; CONTROLLED STUDY; CORRELATION FUNCTION; DEMETHYLATION; DRUG CLEARANCE; DRUG METABOLISM; ENZYME BINDING; ENZYME INACTIVATION; ENZYME INHIBITOR INTERACTION; ENZYME METABOLISM; FEMALE; HUMAN; HUMAN CELL; LIVER MICROSOME; METABOLIC RATE; MICHAELIS MENTEN KINETICS; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RAT;

ANIMALS; CAPILLARY PERMEABILITY; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; DOGS; ENZYME INHIBITORS; FEMALE; GUINEA PIGS; HUMANS; JANUS KINASE 3; MACACA FASCICULARIS; MAST CELLS; MICE; MICROSOMES, LIVER; MODELS, MOLECULAR; PASSIVE CUTANEOUS ANAPHYLAXIS; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SPECIES SPECIFICITY; STEREOISOMERISM;

ANIMALIA; JANUS; UNIDENTIFIED BACULOVIRUS;

EID: 0036136927     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.1.74     Document Type: Article

References (39)

1. LUDI: Rule-based automatic design of new substituents for enzyme inhibitor leads
2. Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice
3. A quantitative HPLC detection method for pharmacokinetic studies of the potent mast cell inhibitor 4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-1)
4. Metabolism and metabolite pharmacokinetics of BRB-I-28, a class Ib antiarrhythmic agent
5. Pharmacokinetic features and metabolism of catphostin C, a naturally occurring perylenequinone with potent antileukemic activity
6. In vivo pharmacokinetics and metabolism of anti-human immunodeficiency virus agent D4T-5′-[p-bromophenyl methoxyalaninyl phosphate] (Sampidine) in mice
7. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research
8. Physiological parameters in laboratory animals and humans
9. New concepts about the mast cells
10. Role of tyrosine kinases in induction of c-jun proto-oncogene in irradiated B-lineage lymphoid cells
11. Clinically significant drug interaction with antituberculosis agents
12. Crystal structure and refinement of cytochrome P450terp at 2.3 A resolution
13. X-ray crystal structure and catalytic properties of Thr252Ile mutant of cytochrome P450cam: Roles of Thr252 and water in the active center
14. CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes
15. The metabolism and kinetics of doxazosin in man, mouse, rat and dog
16. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4
17. In vivo pharmacokinetics and anti-anaphylactic activity of the novel mast cell inhibitor 4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131)
18. Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and FcγRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgEor IgG I-dependent passive anaphylaxis
19. Reversible translocation of 5-lipoxygenase in mast cells upon IgE/antigen stimulation
20. Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions
21. Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis
22. Inhibition of human glioblastoma cell adhesion and invasion by 4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3′-bromo-4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154)
23. Active anaphylaxis in IgE-deficient mice
24. 2+ and purified isozymes in washed permeabilized cells
25. CHAIN-a crystallographic modeling program
26. Reconstitation of interactions between tyrosine kinases and the high affinity IgE receptor which are controlled by receptor clustering
27. An inhibitor of Janus kinase 3: 4-(4′-hydroxyphenylamino)-6.7-dimethoxyquinazoline-1-ium chloride methanol solvate
28. Structure-based design of specific inhibitors of Janus kinase 3
29. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents
30. The metabolic fate of prazosin
31. Role of a Janus kinase 3 (Jak3)-dependent biochemical signaling pathway in platelet activation and aggregation
32. A specific inhibitor of Janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis
33. Pharmacokinetics of TXU (Anti-CD7)-Pokeweed antiviral protein in chimpanzees and adult patients infected with Human Immunodeficiency Virus (HIV)-1
34. In vivo toxicity and pharmacokinetic features of the Janus kinase 3 inhibitor WHI-P131 [(4′hydroxyphenyl)-amino-6,7-dimethoxyquinazoline]
35. P450 gene induction by structurally diverse xenochemicals: Central role of nuclear receptors CAR, PXR, and PPAR
36. Oxidation of the novel oxazolidine antibiotic linezolid in human liver microsomes
37. The metabolic fate of 4-amino-2-(4-butanoylhexahydro-1H-1,4-diazepin-1-y)-16,7-dimethoxyquinazoline HC1